Xinteza, an Israeli biosynthesis technology company, says that it has found a way to produce cannabis type synthesis from other plants in the Cannabacae family that are not known for producing the drug commonly known as marijuana.
Xinteza boasts that it has developed a new on-cannabis plant-derived production system, which the company says is capable of “highly efficient and flawless” end-to-end cannabinoid synthesis.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at firstname.lastname@example.org.
This is all the more significant in the age of marijuana legalization. More and more whole nations and American states are legalizing medical marijuana, or decriminalizing its use – not arresting the users – or outright legalizing the drug. With legalization has come new forms of cultivation making much stronger strains of cannabis.
As with the pharmaceutical field, the cannabis field is now an area of cutthroat competition where firms must stay on top of the latest innovations in the cultivation of cannabis.
Encyclopedia Britannica explains that Cannabis, with 1–3 species, and hops (Humulus), with 3 species, are the most economically important members of the Cannabaceae family.
Cannabis Sativa only produces cannabinoids in its female flowering parts.
Founded in 2019, Xinteza API Ltd. is engaged in the research and discovery of a wide array of new genes and ultra-novel genetic pathways for the biosynthesis of cannabinoids and psychoactive ingredients, and the development of their bio-production methods. Xinteza holds an exclusive license for both cannabinoids and psychoactives from the Weizmann Institute of Science with research led by Prof. Asaph Aharoni and is diligently building an unprecedented portfolio of dozens of related IP assets and patents.
The company’s IP portfolio is based on a license signed with Yeda, the commercial arm of the Weizmann Institute of Science.
“This discovery is a major milestone in the path to uncover and exploit rare and new cannabinoid molecules with potentially novel pharmacological activities,” said Prof. Asaph Aharoni, Xinteza’s Scientific Co-Founder and Head of the Weizmann Institute of Science Plant Metabolomics Lab and of the Institute’s Plant and Environmental Sciences Department.
“Moreover, this alternative non-Cannabaceae production system is significantly more amenable than cannabis to genetic engineering and cellular transformation, allowing greater flexibility in a range of biosynthesis enhancement and optimization processes,” added Prof. Aharoni.